Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Colorectal Neoplasms × trilaciclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 2 Neoplasm Metastasis 2 Urinary Bladder Neoplasms 1 Lung Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Irinotecan 58 Bevacizumab 55 Oxaliplatin 48 Leucovorin 48 Fluorouracil 48 Capecitabine 45 Cetuximab 43 pembrolizumab 22 IFL protocol 15 Nivolumab 11 regorafenib 10 Panitumumab 10 Celecoxib 8 Radiotherapy 7 Cyclophosphamide 7 atezolizumab 6 Surgical Procedures, Operative 6 Folfox protocol 6 Colonoscopy 6 trifluridine tipiracil drug combination 5 Neoadjuvant Therapy 5 Metformin 5 Immunohistochemistry 5 Gemcitabine 5 tislelizumab 4 spartalizumab 4 durvalumab 4 Trastuzumab 4 Mitomycin 4 Interleukin-2 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04607668 2024-11-26

PRESERVE1

G1 Therapeutics, Inc.

Phase 3 Terminated

326 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡